Cargando…
GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
OBJECTIVE: GPR142 agonists are being pursued as novel diabetes therapies by virtue of their insulin secretagogue effects. But it is undetermined whether GPR142's functions in pancreatic islets are limited to regulating insulin secretion. The current study expands research on its action. METHODS...
Autores principales: | Lin, Hua V., Wang, Jingru, Wang, Jie, Li, Weiji, Wang, Xuesong, Alston, James T., Thomas, Melissa K., Briere, Daniel A., Syed, Samreen K., Efanov, Alexander M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001353/ https://www.ncbi.nlm.nih.gov/pubmed/29506910 http://dx.doi.org/10.1016/j.molmet.2018.02.008 |
Ejemplares similares
-
GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism
por: Lin, Hua V., et al.
Publicado: (2016) -
GPR142 Agonists Stimulate Glucose-Dependent Insulin Secretion via Gq-Dependent Signaling
por: Wang, Jingru, et al.
Publicado: (2016) -
Pan-Cancer Analysis and Drug Formulation for GPR139 and GPR142
por: Kaushik, Aman Chandra, et al.
Publicado: (2021) -
Small molecule glucagon release inhibitors with activity in human islets
por: Kalwat, Michael A., et al.
Publicado: (2023) -
The functional impact of G protein-coupled receptor 142 (Gpr142) on pancreatic β-cell in rodent
por: Al-Amily, Israa Mohammad, et al.
Publicado: (2019)